Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non‐t(15;17) subtype

Aims:  The optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who achieved complete remission (CR) and complete consolidation chemotherapy is still controversial. Whether the use of arsenic trioxide (ATO) alone or along with all‐trans retinoic acid (ATRA) improves overall survival (OS) or disease‐free survival (DFS) is still debated.

[1]  R. Arceci,et al.  Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Paternostro,et al.  Treatment of acute promyelocytic leukemia with arsenic trioxide. , 1999, The New England journal of medicine.

[3]  M. Hussein.  Arsenic trioxide , 2001, Medical oncology.

[4]  R. Pfundt,et al.  Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. , 2009, Blood.

[5]  Conrad Me.  Treatment of acute promyelocytic leukemia with arsenic trioxide. , 1999 .

[6]  E. Besa.  Acute promyelocytic leukemia. , 1991, Blood.

[7]  Yuan-fang Liu,et al.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[9]  Yuan-fang Liu,et al.  All-trans retinoic acid As 2 O 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia , 2004 .

[10]  P. Tchounwou,et al.  Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells , 2010, Journal of hematology & oncology.

[11]  M. Conrad.  Treatment of acute promyelocytic leukemia with arsenic trioxide. , 1999, The New England journal of medicine.

[12]  E. Estey,et al.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[14]  M. Boiron,et al.  Acute promyelocytic leukemia: results of treatment by daunorubicin. , 1973, Blood.

[15]  J. Miguel,et al.  Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial , 2003, Leukemia.

[16]  L. Escoda,et al.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. , 2003, Blood.

[17]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[18]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[19]  H. Dombret,et al.  Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. , 2008, Blood.

[20]  J. Esteve,et al.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.

[21]  J. Esteve,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[22]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.